Company: AMTX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001437749-25-015301
Chunk: 13

Company: AEMETIS, INC
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
Energy equity provided by investors who have obtained green card approval have been classified as current debt. As of  March 31, 2025, and  December 31, 2024, $34.7 million and $34.6 million was outstanding, respectively, on the EB-5 Notes.
    
   In 2016 the Company launched its EB-5 Phase II funding (the "EB-5 Phase II Funding") and entered into certain Note Purchase Agreements with Advanced BioEnergy II, LP, a California limited partnership authorized to receive EB-5 equity funding investments. The Company received $4 million in loan funds from Advanced BioEnergy II, LP from 2018 to 2019. As of both  March 31, 2025, and  December 31, 2024, $4.4 million was outstanding on the notes under the EB-5 Phase II funding, respectively.
    
   In  July 2024, in connection with settlement of litigation initiated by a broker previously engaged by Advanced BioEnergy, we entered into an agreement to pay the broker certain of its claimed fees. In  April 2025, that broker initiated litigation against Aemetis, Inc. to collect $2.3 million (plus interest and fees) under the agreement. The liability previously accrued for the amount at issue in the litigation has been reclassified from debt as of  December 31, 2024, to other current liabilities as of  March 31, 2025.

       11

        (Tabular data in thousands, except par value and per share data)

   India Biodiesel Secured and Unsecured Loans. On  November 13, 2023, the Company entered into a secured loan agreement with a trade partner in an amount not to exceed $3.6 that is secured by the fixed and currents assets of the Kakinada Plant. On  November 6, 2023, the Company entered into a short-term loan agreement with a different trade partner in an amount not to exceed $1.27 million. The loans bear interest at 18% that is payable monthly. The loans are repayable on demand by the lender, or by the extended maturity date in  November 2025. As of  March 31, 2025, and  December 31, 2024, the Company had outstanding balances under these agreements totaling $4.0 million and $5